Search Results - "Hunder, N. N."

Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial by Moskowitz, Craig H, Dr Prof, Nademanee, Auayporn, Prof, Masszi, Tamas, Prof, Agura, Edward, Prof, Holowiecki, Jerzy, Prof, Abidi, Muneer H, Prof, Chen, Andy I, Prof, Stiff, Patrick, Prof, Gianni, Alessandro M, Prof, Carella, Angelo, Prof, Osmanov, Dzhelil, Prof, Bachanova, Veronika, Prof, Sweetenham, John, Prof, Sureda, Anna, Prof, Huebner, Dirk, MD, Sievers, Eric L, MD, Chi, Andy, PhD, Larsen, Emily K, MS, Hunder, Naomi N, MD, Walewski, Jan, Prof

“…Summary Background High-dose therapy followed by autologous stem-cell transplantation is standard of care for patients with relapsed or primary refractory…”
Get full text

Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study by Younes, Anas, Dr, Connors, Joseph M, Prof, Park, Steven I, MD, Fanale, Michelle, MD, O'Meara, Megan M, MD, Hunder, Naomi N, MD, Huebner, Dirk, MD, Ansell, Stephen M, Prof

“…Summary Background Roughly 70–80% of patients with advanced stage Hodgkin's lymphoma are cured with various first-line and second-line treatments, including…”
Get full text

Interleukin-21 Has Activity in Patients With Metastatic Melanoma: A Phase II Study by PETRELLA, Teresa M, TOZER, Richard, HAGERMAN, Linda, WALSH, Wendy, EISENHAUER, Elizabeth A, BELANGER, Karl, SAVAGE, Kerry J, WONG, Ralph, SMYLIE, Michael, KAMEL-REID, Suzanne, TRON, Victor, CHEN, Bingshu E, HUNDER, Naomi N

“…We report a multicenter phase II study of patients with metastatic melanoma (MM), evaluating the efficacy, toxicity, progression-free survival (PFS),…”
Get full text

Efficient Cross-Priming of Tumor Antigen-Specific T Cells by Dendritic Cells Sensitized with Diverse Anti-MICA Opsonized Tumor Cells by Groh, Veronika, Li, Yongqing Q., Cioca, Daniel, Hunder, Naomi N., Wang, Wei, Riddell, Stanley R., Yee, Cassian, Spies, Thomas, Thomas, E. Donnall

“…Dendritic cells (DCs) have the capacity to prime tumor-specific T cell responses and are considered as potentially effective vaccines for immunotherapy of…”
Get full text

Brentuximab vedotin does not cause clinically relevant QTc interval prolongation in patients with CD30-positive hematologic malignancies by Han, T. H., Chen, R., Advani, R., Berryman, R. B., Smith, S. E., Forero-Torres, A., Rosenblatt, J. D., Smith, M. R., Zain, J., Hunder, N. N., Engert, A.

“…Purpose Brentuximab vedotin (ADCETRIS ® ), an antibody–drug conjugate, comprises an anti-CD30 antibody conjugated by a protease-cleavable linker to a…”
Get full text

Treatment of Metastatic Melanoma with Autologous CD4+ T Cells against NY-ESO-1 by Hunder, Naomi N, Wallen, Herschel, Cao, Jianhong, Hendricks, Deborah W, Reilly, John Z, Rodmyre, Rebecca, Jungbluth, Achim, Gnjatic, Sacha, Thompson, John A, Yee, Cassian

“…A patient with refractory metastatic melanoma had a complete remission after an infusion of cells from an in vitro–generated clone of autologous CD4+ T cells…”
Get full text

Population Pharmacokinetics of Brentuximab Vedotin in Patients With CD30‐Expressing Hematologic Malignancies by Li, Hong, Han, Tae H., Hunder, Naomi N., Jang, Graham, Zhao, Baiteng

“…Brentuximab vedotin, a CD30‐directed antibody‐drug conjugate (ADC), is approved for treating certain patients with CD30‐expressing hematologic malignancies…”
Get full text

Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection by Muir, Andrew J., Shiffman, Mitchell L., Zaman, Atif, Yoffe, Boris, de la Torre, Andrew, Flamm, Steven, Gordon, Stuart C., Marotta, Paul, Vierling, John M., Carlos Lopez‐Talavera, Juan, Byrnes‐Blake, Kelly, Fontana, David, Freeman, Jeremy, Gray, Todd, Hausman, Diana, Hunder, Naomi N., Lawitz, Eric

“…Interferon lambda 1 (IFN‐λ1) is a type III IFN that produces intracellular responses similar to those of IFN‐α but in fewer cell types because of differences…”
Get full text

Quality of life results from a phase 3 study of brentuximab vedotin consolidation following autologous haematopoietic stem cell transplant for persons with Hodgkin lymphoma by Ramsey, Scott D., Nademanee, Auayporn, Masszi, Tamas, Holowiecki, Jerzy, Abidi, Muneer, Chen, Andy, Stiff, Patrick, Viviani, Simonetta, Sweetenham, John W., Radford, John, Zhu, Yanyan, Bonthapally, Vijayveer, Thomas, Elizabeth, Richhariya, Akshara, Hunder, Naomi N., Walewski, Jan, Moskowitz, Craig H.

“…Summary Brentuximab vedotin (BV) significantly improved progression‐free survival in a phase 3 study in patients with relapsed or refractory Hodgkin lymphoma…”
Get full text

Distinct vascular lesions in giant cell arteritis share identical T cell clonotypes by WEYAND, C. M, SCHÖNBERGER, J, OPPITZ, U, HUNDER, N. N. H, HICOK, K. C, GORONZY, J. J

“…Giant cell arteritis (GCA) is a spontaneous vasculitic syndrome that specifically targets the walls of medium and large arteries. Vascular lesions are…”
Get full text

Recognition of tissue residing antigen by T cells in vasculitic lesions of giant cell arteritis by MARTINEZ-TABOADA, V, HUNDER, N. N. H, HUNDER, G. G, WEYAND, C. M, GORONZY, J. J

“…The objective of this study was to explore the nature of the antigen-specific T cell response in giant cell arteritis by analyzing clonally expanded T cells in…”
Get full text

279 PHARMACOKINETICS OF PEG-INTERFERON LAMBDA (PEG-IFN-λ) IN A DOSE-RANGING PHASE 1B STUDY IN HEPATITIS C PATIENTS by Byrnes-Blake, K.A, Freeman, J.A, Dodds, M.G, Rapalus, L, Pederson, S, Hunder, N, Miller, D.M

Get full text

209P Interim results of a phase I/Ib study of SBT6050 monotherapy and pembrolizumab combination in patients with advanced HER2-expressing or amplified solid tumors by Klempner, S.J., Beeram, M., Sabanathan, D., Chan, A., Hamilton, E., Loi, S., Oh, D-Y., Emens, L.A., Patnaik, A., Kim, J.E., Park, Y.H., Odegard, V., Hamke, S., Jang, G., Jacquemont, C., Hunder, N., Piha-Paul, S.A.

Get full text

Cable cleaning solvents: environmental issues and effective replacements by Wilcox, D.P., Hunder, D.N.

“…The sequence of events used in selecting potential candidates as effective replacements for currently used chlorinated solvents is presented. The authors…”
Get full text

HLA-DRB1 alleles in polymyalgia rheumatica, giant cell arteritis, and rheumatoid arthritis by Weyand, C M, Hunder, N N, Hicok, K C, Hunder, G G, Goronzy, J J

“…Immunogenetic analysis has demonstrated that giant cell arteritis (GCA) and rheumatoid arthritis (RA) are associated with 2 different domains of the HLA-DR4…”
Get more information

Phase 1/2 study of PRO1184, a novel folate receptor alpha-directed antibody-drug conjugate, in patients with locally advanced and/or metastatic solid tumors by Call, Justin A, Orr, Douglas W., Anderson, Ian Churchill, Richardson, Debra L., Chen, Zhu, Ma, Sharon, Hunder, Naomi N. H., Hamilton, Erika P.

“…TPS3157 Background: PRO1184 is an antibody-drug conjugate (ADC) directed to folate receptor alpha (FRα), a cell surface antigen overexpressed in multiple…”
Get full text

Interleukin-21 (IL-21) activity in patients (pts) with metastatic melanoma (MM) by Petrella, T. M., Tozer, R., Belanger, K., Savage, K. J., Wong, R., Kamel-Reid, S., Tron, V., Chen, B., Hunder, N. N., Eisenhauer, E. A.

“…Abstract only…”
Get full text

Phase II study of recombinant IL-21 (rIL-21) plus sorafenib as second- or third-line therapy for metastatic renal cell cancer (mRCC): Final results by Bhatia, S., Heath, E., Puzanov, I., Miller, W., Curti, B., Gordon, M., Ernstoff, M., Hausman, D., Hunder, N., Thompson, J.

“…Abstract only 3023 Background: Despite the positive impact of targeted therapies on treatment for mRCC, the efficacy of these agents appears to decrease beyond…”
Get full text

Updated Efficacy and Safety Data from the AETHERA Trial of Consolidation with Brentuximab Vedotin after Autologous Stem Cell Transplant (ASCT) in Hodgkin Lymphoma Patients at High Risk of Relapse by Sweetenham, John W., MD, FRCP, Walewski, Jan, MD, Nadamanee, Auayporn, MD, Masszi, Tamas, MD, PhD, Agura, Edward, MD, Holowiecki, Jerzy, MD, PhD, Abidi, Muneer H., MD, Chen, Andy I., MD, PhD, Stiff, Pat, MD, Viviani, Simonetta, Carella, Angelo, MD, Osmanov, Dzhelil, MD, Bachanova, Veronika, MD, PhD, Sureda, Anna, MD, PhD, Huebner, Dirk, MD, Larsen, Emily K., MS, Hunder, Naomi N., MD, Moskowitz, Craig H., MD

Get full text

Recombinant IL-21 (rIL-21) in combination with sorafenib: Interim results from a phase 1/2 study in patients with metastatic renal cell cancer (mRCC) by Bhatia, S., Curti, B. D., Gordon, M. S., Quinn, D. I., Thompson, J. A., DeVries, T. A., Dodds, M. G., Hunder, N. N., Hausman, D. F.

“…Abstract only…”
Get full text